CAS 1137916-97-2

(S)-3-((6-(Ethylsulfonyl)pyridin-3-yl)oxy)-5-((1-hydroxypropan-2-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide methanesulfonate

CAS : 1137916-97-2

(S)-3-((6-(Ethylsulfonyl)pyridin-3-yl)oxy)-5-((1-hydroxypropan-2-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide methanesulfonate

Degré de pureté : 98%

Masse moléculaire : 556.62g/mol

Ref: 54-OR1073914

MK-0941

CAS : 1137916-97-2

MK-0941 is a potential therapeutic for the treatment of type 2 diabetes. It is a novel, orally active, small molecule that has been shown to reduce blood glucose levels in preclinical models. MK-0941 targets pancreatic and hepatic steatosis by inhibiting the uptake of triglycerides from plasma into these tissues. MK-0941 also increases insulin sensitivity in vitro and in vivo. This drug has been studied as monotherapy at doses of 0.1, 1, or 10 mg/kg and as combination therapy with metformin at doses of 5 or 25 mg/kg in db/db mice and wild-type mice. The study drug was well tolerated up to 10 mg/kg without any adverse effects on body weight or food intake observed.
MK-0941 has shown promising results in lowering blood glucose levels and improving insulin sensitivity when administered alone or in combination with metformin at high doses.

Formule : C₂₂H₂₈N₄O₉S₂

Degré de pureté : Min. 95%

Masse moléculaire : 556.61 g/mol

Ref: 3D-MVB91697

MK-0941

CAS : 1137916-97-2

MK-0941 is an orally active and allosteric glucokinase activator, has potential in the treatment of type 2 diabetes.

Formule : C₂₂H₂₈N₄O₉S₂

Couleur et forme : Solid

Masse moléculaire : 556.61

Ref: TM-T12057